Meity Ardiana, Meity and Asiyah Nurul Fadila, - and Zakirah Zuhra, - and Nabilla Merdika Kusuma, - and Made Edgard Surya Erlangga Rurus, - and Delvac Oceandy, - (2023) Non-coding RNA therapeutics in cardiovascular disease and risk factors: Systematic review. KeAi Journals, 8 (4). pp. 487-506. ISSN 2468-0540

	Text (Artikel) 20. Non-coding RNA therapeutics.pdf Download (2MB)
	Text (Turnitin) 20. Non-coding RNA therapeutics-1-48.pdf Download (4MB)
	Text (Kualitas Karil & Kesesuaian Bidang Ilmu) 18. karil.pdf Download (458kB)
	Text (Bukti Korespondensi) 18. korespondensi.pdf Download (2MB)

Abstract

Abstract At present, RNA-based therapy which includes therapies using non-coding RNAs (ncRNAs), antisense oligonucleotides (ASOs), and aptamers are gaining widespread attention as possible ways to target genes in various cardiovascular diseases (CVDs), thereby serving as a promising therapeutic approach for CVDs and risk factors management. However, data are primarily in an early stage. A systematic review was carried out using literature from several databases (Pubmed, Cochrane, Scopus, and DOAJR) following the PRISMA guidelines. Of the 64 articles reviewed, 39 papers were included in this review with three main types of RNAs: aptamers, antisense oligonucleotides (ASOs), and small-interfering RNA (siRNA). All studies were human clinical trials. RNA-based therapies were demonstrated to be efficacious in treating various CVDs and controlling cardiovascular risk factors. They are generally safe and well-tolerated. However, data are still in the early stage and warrant further investigation.

Actions (login required)

View Item